Leucémie lymphoïde chronique : une décennie de thérapies ciblées (notice n° 660009)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01937cam a2200325 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121192112.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Guièze, Romain |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Leucémie lymphoïde chronique : une décennie de thérapies ciblées |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 46 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | La dernière décennie a été marquée par l’émergence de plusieurs classes de thérapies ciblées dans la leucémie lymphoïde chronique. Les inhibiteurs de la signalisation du récepteur B à l’antigène sont essentiellement représentés par les inhibiteurs de tyrosine kinase de Bruton (BTK) qui ont fait l’objet d’un développement rapide et occupent désormais la première ligne. La seconde classe est à ce jour représenté par l’inhibiteur de BCL2, vénétoclax. Leur combinaison s’avère très efficace et pourrait bientôt constituer un gold standard. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The last decade has seen the emergence of several classes of targeted therapies in chronic lymphocytic leukaemia. Inhibitors of B-receptor antigen signalling are mainly represented by BTK inhibitors, which have undergone rapid development and now occupy the first line. The second class is currently represented by the BCL2 inhibitor vénétoclax. Their combination is proving to be very effective and may soon become a gold standard. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | acalabrutinib |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lymphoïde chronique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ibrutinib |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | leucémie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Thérapies ciblées |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | zanubrutinib |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vénétoclax |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | acalabrutinib |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Targeted therapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ibrutinib |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | zanubrutinib |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vénétoclax |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chronic lymphocytic leukemia |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 29 | N° Supp 1 | 2023-03-15 | p. 23-27 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2023-HS1-page-23?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2023-HS1-page-23?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux